Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 06 2021 - 10:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of January 2021
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot 7670104,
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the Registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Purple Biotech Ltd. (the “Company” or the “Registrant”) is
announcing that it has made available an updated Company
Presentation on its website. A copy of the updated Company
Presentation is attached hereto as Exhibit 99.1 and may be viewed
at the Company’s website at www.kitovpharma.com.
Exhibits
Incorporation by Reference
This Form 6-K, including all exhibits attached hereto, is hereby
incorporated by reference
into each of the Registrant’s Registration Statement on
Form S-8 filed with the
Securities and Exchange Commission on May 20, 2016 (Registration
file number 333-211478), the Registrant’s Registration Statement
on
Form S-8 filed with the
Securities and Exchange Commission on June 6, 2017 (Registration
file number 333-218538), the Registrant’s Registration Statement
on
Form F-3, as amended,
originally filed with the Securities and Exchange Commission on
July 16, 2018 (Registration file number 333-226195), the
Registrant’s Registration Statement on
Form S-8 filed with the
Securities and Exchange Commission on March 28, 2019 (Registration
file number 333-230584), the Registrant’s Registration Statement
on
Form F-3 filed with the
Securities and Exchange Commission on September 16, 2019
(Registration file number 333-233795), the Registrant’s
Registration Statement on
Form F-3 filed with the
Securities and Exchange Commission on December 2, 2019
(Registration file number 333-235327), the Registrant’s
Registration Statement on
Form F-3 filed with the
Securities and Exchange Commission on May 13, 2020 (Registration
file number 333- 238229), the Registrant’s Registration Statement
on
Form S-8 filed with the
Securities and Exchange Commission on May 28, 2020 (Registration
file number 333-238481) and each of the Registrant’s Registration
Statements on Form F-3 filed with the Securities and Exchange
Commission on July 10, 2020 (Registration file numbers
333-239807
and
333-233793), to be a part thereof from the
date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or
furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
January
6, 2021 |
PURPLE
BIOTECH LTD. |
|
|
|
|
By: |
/s/
Isaac Israel |
|
|
Isaac
Israel |
|
|
Chief
Executive Officer |
2